10-Q: AIM ImmunoTech Narrows Losses Amid Clinical Progress, Funding Challenges

AIM ImmunoTech reported reduced net losses for Q3 and the first nine months of 2025, driven by cost-cutting and a legal fee settlement, despite declining revenue and ongoing liquidity concerns.

Summary

• Net loss for the three months ended September 30, 2025, decreased by 11% to $3.284 million from $3.700 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, decreased by 14% to $9.783 million from $11.353 million in the prior year period.
• Revenue from clinical treatment programs decreased to $26,000 for Q3 2025 (from $35,000 in Q3 2024) and to $67,000 for the nine months ended September 30, 2025 (from $125,000 in the prior year period).
• Interest and other income significantly increased by $2.334 million in Q3 2025, primarily due to a $3.041 million legal fee forgiveness agreement.
• Research and development (R&D) costs decreased by $830,000 in Q3 2025 and $1.672 million for the nine months ended September 30, 2025, reflecting reduced clinical, manufacturing, quality control, and regulatory expenses.
• General and administrative (G&A) expenses decreased by $1.281 million in Q3 2025 and $3.655 million for the nine months ended September 30, 2025, due to ongoing cost-cutting measures, mainly legal fees.
• The company reported a working capital deficit of $1.468 million and a stockholders' deficit of $6.077 million as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• A public offering on July 31, 2025, generated gross proceeds of approximately $8.000 million through the issuance of common stock and Class E and F warrants, but also resulted in a $3.977 million loss on issuance of warrants and a $7.302 million warrant liability.
• The company successfully executed a 1-for-100 reverse stock split on June 10, 2025, to regain compliance with NYSE American's low selling price rule, and trading was reinstated on June 17, 2025.
• Clinical trials for Ampligen in pancreatic cancer (DURIPANC study) showed positive mid-year safety and efficacy updates, with 64% of eligible subjects having overall survival greater than 6 months.
• The AMP-270 Phase 2 pancreatic cancer study was placed on hold and suspended in February 2025, pending additional data from the DURIPANC trial.
• The Phase 2 study of Ampligen for Post-COVID conditions (AMP-518) completed enrollment, and final results posted in January 2025 support its potential for moderate-to-severe fatigue, showing a significant improvement in the Six-Minute Walk Test for a subset of patients.
• Two ovarian cancer studies were terminated: one Phase 2 due to lack of funding and another Phase 1/2a due to funding ending, while a separate Phase 2 ovarian cancer study reported a 45% Objective Response Rate and 7.8 months median Progression-Free Survival in platinum-sensitive subjects.
• Legal proceedings regarding attorney fees and a complaint against BioLife Plasma Services, L.P. have concluded, with the company's appeals unsuccessful but no further counterclaims filed.

Sentiment

Score: 3

Explanation: The company faces severe liquidity issues, a significant stockholders' deficit, and ongoing delisting risks, despite some positive clinical trial updates and reduced net losses. The substantial warrant liability and declining revenue are major concerns, indicating a precarious financial position and high reliance on future capital raises.

Positives

• Net loss decreased by 11% in Q3 2025 and 14% for the nine months ended September 30, 2025, compared to the prior year periods.
• Interest and other income increased significantly by $2.334 million in Q3 2025, largely due to a $3.041 million legal fee forgiveness agreement.
• Research and development (R&D) expenses decreased by $830,000 in Q3 2025 and $1.672 million for the nine months ended September 30, 2025, indicating improved cost management.
• General and administrative (G&A) expenses decreased by $1.281 million in Q3 2025 and $3.655 million for the nine months ended September 30, 2025, due to successful cost-cutting measures.
• The DURIPANC Phase 1b/2 clinical trial for pancreatic cancer showed positive mid-year safety and efficacy, with no significant toxicity and 64% of eligible subjects achieving overall survival greater than 6 months.
• A Phase 2 study for advanced recurrent ovarian cancer reported a 45% Objective Response Rate and a median Progression-Free Survival of 7.8 months in platinum-sensitive subjects.
• The AMP-518 Phase 2 study for Post-COVID conditions demonstrated significant potential for Ampligen in treating moderate-to-severe fatigue, with a subset of patients showing a mean improvement of 139 meters in the Six-Minute Walk Test.
• The company successfully executed a 1-for-100 reverse stock split, resolving the NYSE American delisting issue related to low selling price and reinstating trading.
• A new patent (No. 12,102,649) was granted in October 2024 covering compositions and methods for treating endometriosis with Ampligen.
• A patent (expires January 25, 2041) was received in June 2025 covering methods for manufacturing therapeutic double-stranded RNA products, including Ampligen, further securing control over its synthesis.

Negatives

• Revenue from clinical treatment programs decreased by $9,000 in Q3 2025 and $58,000 for the nine months ended September 30, 2025, indicating declining patient participation.
• The company reported a working capital deficit of $1.468 million and a stockholders' deficit of $6.077 million as of September 30, 2025.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern for at least one year.
• The public offering on July 31, 2025, resulted in a $3.977 million loss on issuance of warrants and a $7.302 million warrant liability on the balance sheet.
• The AMP-270 Phase 2 pancreatic cancer study was placed on hold and suspended due to a business decision, indicating a setback in this development area.
• Two ovarian cancer studies were terminated due to lack of funding or funding ending, highlighting ongoing financial constraints for clinical development.
• The production of Alferon N Injection Active Pharmaceutical Ingredient (API) is currently on hold with no definitive timetable to resume, and commercial sales will not resume until new batches are produced and released.
• Commercialization of Ampligen in Argentina for CFS is delayed due to ANMAT's internal processes and the country's hyper-inflation and currency devaluation, shifting focus to pancreatic cancer approval instead.
• Marketable securities decreased significantly to $62,000 as of September 30, 2025, from $2.276 million as of December 31, 2024.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to incurred losses from operations, net cash used in operating activities, and a working capital deficit.
• Failure to regain compliance with NYSE American's stockholders' equity requirement of $6.000 million by June 11, 2026, could lead to delisting of common stock.
• The company's ability to raise sufficient capital through its plan or other means is uncertain, which could prevent it from regaining compliance with listing standards and continuing operations.
• Clinical trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities, and there is no assurance that current or planned trials will be successful or yield favorable data.
• Results obtained in animal models do not necessarily predict results in humans, and human clinical trials are necessary to prove efficacy.
• Operating in foreign countries carries risks, including potential difficulties in enforcing intellectual property rights and adverse effects from economic conditions like hyper-inflation and currency devaluation (e.g., Argentina).
• The company relies heavily on financing activities, and there is no assurance of attaining necessary future funding.
• The warrant liability of $7.302 million, while not requiring cash expenditure for redemption, represents a significant accounting liability on the balance sheet.
• The production of Alferon N Injection API is on hold, and there is no definitive timetable to resume, impacting future commercial sales of this product.

Future Outlook

The company intends to prioritize clinical work in trials authorized by the FDA or EMA to support potential future New Drug Applications (NDAs), with pancreatic cancer having priority. It plans to pursue a study of a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist, seeking collaborative grants. The AMP-270 pancreatic cancer study may be redesigned or amended pending additional data from the ongoing DURIPANC clinical trial. The company plans a comprehensive follow-up with the FDA regarding Ampligen for ME/CFS, adjusting its approach to concentrate on specific symptoms. Commercial sales of Alferon N Injection will not resume until new batches are produced and released by the FDA, with no definitive timetable for production. The company continues to explore new efficiencies in polymer production for Ampligen and seeks licensing, collaboration, or joint venture partners for global commercialization.

Management Comments

• "In managements opinion, all adjustments necessary for a fair presentation of its consolidated financial statements have been included. Such adjustments consist of normal recurring items."
• "Management evaluated the conditions and the significance in relation to the Companys ability to meet its obligations and noted that all outstanding debt is current as of September 30, 2025."
• "We believe that this pre-clinical and clinical work to date — combined with the ever-growing threat of Avian influenza — strongly supports our decision to move forward with this second Ampligen and FluMist study in humans."
• "The results support our belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for any follow-up clinical trial."
• "AIM therefore believes that any future trial design should focus on Ampligens therapeutic potential for subjects whose Long COVID-related fatigue can be categorized as moderate or worse."
• "We believe that the analysis supports a dual mechanism of action when Ampligen is used as a prophylactic therapy against Ebola Virus Disease."
• "While the warrants met the technical requirements of the accounting standard, the ultimate redemption of the warrants will not require any cash expenditure or transfer or assets by us. Any warrant exercises would result in additional cash and equity to us because we have a sufficient number of authorized and unissued shares available to satisfy the warrant exercises in shares."

Industry Context

AIM ImmunoTech operates in the highly competitive and capital-intensive immuno-pharma sector, focusing on niche areas like pancreatic cancer, ME/CFS, Post-COVID conditions, and antiviral therapies. The company's strategy of combining Ampligen with checkpoint inhibitors aligns with a broader industry trend towards combination therapies in oncology to enhance treatment efficacy. Its pursuit of an avian influenza vaccine adjuvant also reflects ongoing global health concerns and the need for preparedness against emerging viral threats. However, the company faces significant challenges common to small biotechs, including substantial R&D costs, reliance on external funding, and the long, uncertain path to regulatory approval and commercialization. The termination of some trials due to funding issues underscores the intense financial pressures in this industry, while the positive data in pancreatic cancer and Post-COVID conditions, if sustained and replicated, could position Ampligen favorably in areas with unmet medical needs.

Comparison to Industry Standards

• The DURIPANC study's finding of 64% overall survival (OS) greater than 6 months in eligible pancreatic cancer subjects, when Ampligen is combined with durvalumab, is notable given the aggressive nature of pancreatic cancer, which typically has a very poor prognosis. For example, standard of care for metastatic pancreatic cancer often yields median OS in the range of 6-12 months, making Ampligen's contribution to extending survival a potentially significant finding, though direct comparisons to specific competitor drugs or trials are not provided in the filing.
• The AMP-518 study's observation of a mean improvement of 139 meters in the Six-Minute Walk Test for a subset of Post-COVID fatigue patients (compared to 91 meters in placebo) suggests a clinically meaningful effect. This could be compared to other emerging therapies for Long COVID, such as those being developed by companies like Vir Biotechnology or Pfizer, which are exploring various mechanisms to address post-viral syndromes, though specific comparative data is not detailed in the filing.
• The reported Objective Response Rate (ORR) of 45% and median Progression-Free Survival (PFS) of 7.8 months in platinum-sensitive recurrent ovarian cancer patients treated with cisplatin, pembrolizumab, and Ampligen are promising. For context, typical ORRs for platinum-sensitive recurrent ovarian cancer with chemotherapy alone can range from 30-60%, and PFS can vary widely. The combination therapy's results suggest a competitive profile, potentially comparable to or better than some existing second-line treatments, but without direct head-to-head data against specific competitor regimens (e.g., those involving PARP inhibitors or other immunotherapies from companies like AstraZeneca or Merck), a definitive assessment is challenging.

Corporate Governance

Legal Proceedings

• AIM ImmunoTech, Inc. v. Tudor, et al.: The Appellate court upheld the lower court's decision on April 4, 2025, regarding attorneys' fees and costs. Funds held in escrow were disbursed, and $74,581.38 was returned to AIM on June 5, 2025. The matter is now concluded.
• Complaint against BioLife Plasma Services, L.P.: The Superior Court of Pennsylvania affirmed the dismissal of the company's complaint on July 28, 2025. BioLife did not re-assert its counterclaim for $96,000 within the 30-day period, and the time to do so has expired. The matter is now concluded.

Related Party Transactions

• The company issued common stock as a substitute for cash salaries to certain executives and directors as part of a cash conservation strategy. For the nine months ended September 30, 2025, stock issued as compensation totaled $60,000 (4,242 shares post reverse split).

Stakeholder Impact

• Shareholders: Experienced significant dilution from capital raises and a 1-for-100 reverse stock split. Face ongoing risk of delisting if stockholders' equity requirements are not met. Potential for future value if Ampligen's clinical programs succeed.
• Employees: Participate in a 401(k) plan with company contributions. Some executives and directors received common stock as compensation, impacting their equity holdings.
• Customers/Patients: Continued access to Ampligen through expanded access programs. Potential for new treatment options if clinical trials for pancreatic cancer, Post-COVID conditions, and antiviral therapies are successful.
• Creditors: Streeterville Capital LLC, a lender, has settled portions of outstanding loan obligations through the issuance of common stock, indicating a reliance on equity for debt management.
• Suppliers/Vendors: An agreement with a vendor resulted in $3.041 million of previously billed legal fees being forgiven in exchange for payments, impacting the vendor's receivables and the company's liabilities.

Next Steps

• Continue enrollment and dosing in Phase 2 of the DURIPANC study for pancreatic cancer.
• Potentially redesign or amend the AMP-270 pancreatic cancer study pending additional data from the DURIPANC trial.
• Pursue a study of a potential avian influenza combination therapy of Ampligen and AstraZeneca's FluMist.
• Seek collaborative grants from government and industry to defray the cost of the avian influenza study.
• Conduct a comprehensive follow-up with the FDA regarding Ampligen as a treatment for ME/CFS, focusing on specific symptoms.
• Continue efforts to understand existing data and advance the development of new data to support future FDA filings for Ampligen.
• Complete the validation of the polymer production process with Sterling Pharma Solutions for Ampligen manufacturing.
• Identify a new manufacturing approach and submit satisfactory stability and quality release data to the FDA to resume commercial sales of Alferon N Injection.
• Work with Filaxis on an approval in Argentina for pancreatic cancer, shifting focus from CFS due to economic conditions.
• Continue to utilize the Equity Distribution Agreement with Maxim Group LLC and the Equity Purchase Agreement with Atlas Sciences, LLC, for capital raising.
• Regain compliance with NYSE American's stockholders' equity requirement of $6.000 million by June 11, 2026.

Key Dates

Recommendation

Despite a reduction in net losses and some positive clinical trial updates, AIM ImmunoTech faces severe and persistent financial challenges, including a substantial working capital deficit and stockholders' deficit, raising significant doubt about its ability to continue as a going concern. The company's reliance on continuous capital raises, coupled with declining revenue and the recognition of a large warrant liability, indicates a precarious financial position. While the reverse stock split temporarily resolved a delisting issue, it does not address the fundamental lack of profitability or sustainable cash flow. The termination or suspension of multiple clinical trials due to funding issues further highlights operational and financial instability. Given the high-risk profile, ongoing dilution, and fundamental financial weakness, a seasoned investor would likely recommend selling the stock.

Keywords

Ampligen, rintatolimod, immuno-oncology, pancreatic cancer, Post-COVID conditions, ME/CFS, clinical trials, biotechnology, pharmaceuticals, SEC filing, 10-Q, going concern, capital raise, NYSE American, Alferon N Injection, antiviral, warrants, stock split